Following a third report of fatal disseminated vaccine strain varicella-zoster virus infection following Zostavax administration, the Therapeutic Goods Administration (TGA) is reminding health professionals that Zostavax should not be used in people with compromised immune function.
Healthcare professionals should carefully assess patients for potentially immunocompromising conditions. The Australian Immunisation Handbook has recently been updated to provide more detailed guidance on the use of Zostavax in patients who are immunocompromised or on immunosuppressive therapy, including:
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
